A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC).

Jianming Xu(Chinese PLA General Hospital), Qian Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yangzhi Su, Rusen Zhao(Central Hospital of Zibo), Rongrui Liu(Chinese PLA General Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Wu(Nanjing Medical University), Xiaojun Xiang(Ministry of Agriculture and Rural Affairs), Xionghui Li, Xiaoyan Lin(Fujian Medical University), Feng Ye(Shanghai Sunshine Rehabilitation Center), Jianhong Wang(Nantong Tumor Hospital), Baohong Guo, Yanqiao Zhang(Harbin Medical University), Shegan Gao(First Affiliated Hospital of Henan University of Science and Technology), Huiting Xu(Hubei Cancer Hospital), Nong Xu(First Affiliated Hospital Zhejiang University), Suxia Luo(Henan Cancer Hospital)
Journal of Clinical Oncology
June 1, 2022
10.1200/jco.2022.40.16_suppl.4040
Cited by 6

Related Papers

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687